Etretinateisanaromaticretinoidthatexhibitsanti-inflammatoryandanticanceractivities.Etretinatewaspreviouslyclinicallyusedtotreatpsoriasisbuthassincebeenwithdrawnduetohighincidenceofbirthdefects;itiscurrentlyconsideredteratogenic.ThiscompoundactsasanagoNISTatRARsandRXRs.EtretinateshowssomepotentialinthetreatmentofcutaneousT-celllymphoma.
| CasNo. | 54350-48-0 |
|---|---|
| Purity | ≥98% |
| Formula | C23H30O3 |
| FormulaWt. | 354.49 |
| ChemicalName | (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoicacidethylester |
| IUPACName | ethyl(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate |
| Synonym | Tegison;Tigason |
| MeltingPoint | 104-105°C |
| Appearance | YelloworGreenish-YellowCrystallinePowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| MSDS | E7668MSDSPDF |
|---|---|
| InfoSheet | E7668InfoSheetPDF |
BurgG,DummerR.HistoricalperspectiveontheuseofretinoidsincutaneousT-celllymphoma(CTCL).ClinLymphoma.2000Nov;1Suppl1:S41-4.PMID:11707863.
SauratJH.Retinoidsandpsoriasis:novelissuesinretinoidpharmacologyandimplicationsforpsoriasistreatment.JAmAcadDermatol.1999Sep;41(3Pt2):S2-6.PMID:10459139.
